ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVBP ArriVent BioPharma

Pre-Mkt 06-05 06:02:13 EDT

33.09

+3.31

+11.11%

盘前31.85

-1.24-3.75%

04:01 EDT

High33.62	Low29.49	Vol744.74K
Open29.49	D1 Closing29.78	Amplitude13.85%
Mkt Cap1.53B	Tradable Cap989.09M	Total Shares46.37M
T/O24.35M	T/O Rate2.49%	Tradable Shares29.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":33.09,"timestamp":1780603200000,"preClose":29.78,"halted":0,"volume":744735,"hourTrading":{"tag":"盘前","latestPrice":31.85,"preClose":33.09,"latestTime":"04:01 EDT","volume":1,"amount":31.85,"timestamp":1780646462925,"change":-1.24,"changeRate":-0.037474,"amplitude":0},"delay":0,"changeRate":0.11114842175957025,"floatShares":29890900,"shares":46368442,"eps":-3.520584,"marketStatus":"Pre-Mkt","change":3.31,"latestTime":"06-05 06:02:13 EDT","open":29.49,"high":33.616,"low":29.49,"amount":24348400.34781,"amplitude":0.138549,"askPrice":33.86,"askSize":1,"bidPrice":33.09,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-3.520584,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780666200000},"marketStatusCode":1,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":33.09,"preHourTrading":{"tag":"盘前","latestPrice":31.85,"preClose":33.09,"latestTime":"04:01 EDT","volume":1,"amount":31.85,"timestamp":1780646462925,"change":-1.24,"changeRate":-0.037474,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":33.11,"preClose":33.09,"latestTime":"19:21 EDT","volume":7852,"amount":259830.5664,"timestamp":1780615304734,"change":0.02,"changeRate":0.000604,"amplitude":0.000604},"volumeRatio":0.8101700005300293,"impliedVol":1.3113,"impliedVolPercentile":0.796},"requestUrl":"/m/hq/s/AVBP/tweets","defaultTab":"tweets","newsList":[{"id":"2641636169","title":"ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641636169","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641636169?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:32","pubTimestamp":1780590770,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ($AVBP) announced an update on their ongoing clinical study. The phase I study “An Open-Label, Multi-Center, Dose Escalati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivents-mrg007-phase-i-trial-progress-adds-long-term-option-value-for-avbp-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivents-mrg007-phase-i-trial-progress-adds-long-term-option-value-for-avbp-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","BK4097","ISBC","LU2065732104.USD","PRGS","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640502841","title":"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640502841","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640502841?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:00","pubTimestamp":1780578045,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-mineralys-therapeutics-inc-mlys-and-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-mineralys-therapeutics-inc-mlys-and-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","HCSG","XLV","LU0170899867.USD","BK4588","AVBP","LU0029874061.USD","BK4613","BK4139","LU0128526141.USD","LU0058720904.USD","MLYS","LU1989764664.SGD","LU0266013472.USD","BK4167","BK4534","LU1989764748.USD","BK4504","VEEV","BK4585","LABU","XBI","BK4528","LU0289739699.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640728966","title":"Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640728966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640728966?lang=en_us&edition=fundamental","pubTime":"2026-06-02 01:55","pubTimestamp":1780336534,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt maintained a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $45.00. Schmidt covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959230","title":"Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959230?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:55","pubTimestamp":1780314944,"startTime":"0","endTime":"0","summary":"Analyst Jeet Mukherjee of BTIG maintained a Buy rating on ArriVent BioPharma, Inc., retaining the price target of $42.00. Jeet Mukherjee has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-arrivent-maintains-42-price-target-on-firlotinib-confidence-after-sunvozertinib-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-arrivent-maintains-42-price-target-on-firlotinib-confidence-after-sunvozertinib-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639767187","title":"ArriVent BioPharma Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2639767187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639767187?lang=en_us&edition=fundamental","pubTime":"2026-05-30 01:01","pubTimestamp":1780074060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 13:01 ET (17:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636898531","title":"Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636898531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636898531?lang=en_us&edition=fundamental","pubTime":"2026-05-20 07:10","pubTimestamp":1779232231,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM) and ArriVent BioPharma, Inc. (AVBP)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","AVBP","BK4539","BK4585","BK4137","LU0029874061.USD","XBI","LU0128526141.USD","LABU","BK4112","BK4581","CLYM","BLSX","BLSG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636018499","title":"LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636018499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636018499?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:46","pubTimestamp":1779036389,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on ArriVent BioPharma, Inc. yesterday and set a price target of $42.00. According to Ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635973714","title":"ArriVent BioPharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2635973714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635973714?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:56","pubTimestamp":1778698560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 14:56 ET (18:56 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634255366","title":"ArriVent BioPharma Updates At-The-Market Equity Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634255366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634255366?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:53","pubTimestamp":1778536380,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has shared an update. On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement with the U.S. Se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-updates-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-updates-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","AVBP","BK4585","BK4139","BK4588","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230051","title":"ArriVent Biopharma launches ATM offering for up to $250 million via Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230051","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230051?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:44","pubTimestamp":1778532248,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma filed a prospectus supplement for its existing at-the-market offering program, authorizing sales of up to USD 250 million of common stock.Jefferies will act as sales agent for the share sales from time to time under an Open Market Sale Agreement dated Feb. 3, 2025.Program will operate off ArriVent’s automatic shelf registration statement on Form S-3ASR filed Feb. 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLbSdLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230737","title":"Arrivent Biopharma Inc - Enters Open Market Sale Agreement for Offer and Sell Common Stock up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230737?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:42","pubTimestamp":1778532174,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O1JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634923041","title":"ArriVent Biopharma posts corporate presentation on late-stage oncology pipeline, firmonertinib lead program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634923041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634923041?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:34","pubTimestamp":1778531655,"startTime":"0","endTime":"0","summary":"ArriVent highlighted firmonertinib as lead program, with topline data expected in mid-2026 from global registrational Phase 3 FURVENT trial in first-line EGFR exon 20 insertion mutant NSCLC.FURVENT enrolled 398 patients versus target 375, with progression-free survival by blinded independent central review as primary endpoint.For first-line EGFR PACC mutant NSCLC, global Phase 3 ALPACCA targets 480 patients, comparing firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib.ArriVent reported cash and cash equivalents of USD 326.4 million as of March 31, 2026.ADC pipeline update included ARR-217 in Phase 1 with dose-escalation completion planned in 2H 2026, alongside ARR-002 with US IND clearance and Phase 1 initiation planned in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8tWg01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237265","title":"ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237265?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:20","pubTimestamp":1778530817,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings SummaryArriVent BioPharma Inc AVBP.OQ reported a quarterly adjusted loss of 96 cents per share for the quarter ended Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634517237","title":"ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634517237","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634517237?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530353,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.86) by 11.63 percent. This is a 49.47 percent increase over losses of $(1.90) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52468664/arrivent-biopharma-q1-eps-0-96-misses-0-86-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232590","title":"ArriVent Q1 net loss narrows 32.7% to $43.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232590?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:02","pubTimestamp":1778529733,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma posted a net loss of USD 43.3 million, narrowing from USD 64.4 million a year earlier; loss per share improved to USD 0.96 from USD 1.90.R&D expense fell to USD 37.6 million from USD 61.3 million, while G&A expense rose to USD 8.5 million from USD 5.5 million.Cash and investments totaled USD 326.4 million as of March 31, expected to fund operations into 4Q 2027.Topline Phase 3 monotherapy data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected in mid-2026; Phase 3 ALPACCA study in EGFR PACC mutant NSCLC continues enrolling globally.FDA cleared IND for ARR-002, with first patient dosing planned in 2H 2026; ARR-217 Phase 1 dose escalation in GI cancers continues after first patient was dosed in March 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL79SDf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","IE00BN0W2T93.GBP","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4112","BK4139","IE00BN0W2V16.EUR","AVBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634368232","title":"Arrivent Biopharma Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634368232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634368232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA1FRJG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634325842","title":"Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634325842","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634325842?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"-- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR. -- IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b. tetravalent ADC, advances into the clinic and plans to dose its first. patient in 2H 2026, initially for ovarian and endometrial cancers. -- ARR-002's superior anti-tumor activity and favorable tolerability vs.single-target or bivalent approaches in preclinical ovarian cancer models. Dr. Yao continued, \"We also presented preclinical data for our antibody-drug conjugate , ARR-002 at AACR. This novel MUC16/NaPi2b dual-targeting tetravalent ADC demonstrated synergistic anti-tumor activity compared to single-target and bivalent ADCs, along with a favorable tolerability profile, supporting its best-in-class potential. Following the recent clearance of our Investigational New Drug  application by the U.S. Food and Drug Administration , we plan to initially advance ARR-002 into the clinic for ovarian and endometrial cancers. Our balance sheet contin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4139","BK4231","AVBP","IND","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468945","title":"ArriVent BioPharma Inc  expected to post a loss of 89 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468945","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468945?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:42","pubTimestamp":1778254927,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc  expected to post a loss of89cents a share - Earnings Preview ArriVent BioPharma Inc AVBP.OQ AVBP.O is expected to  show no change in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633304174","title":"H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633304174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633304174?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:59","pubTimestamp":1778237996,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $44.00. According to TipRa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633787221","title":"ArriVent Biopharma announces FDA clearance of ARR-002 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2633787221","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633787221?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:45","pubTimestamp":1778179502,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravale...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-announces-fda-clearance-of-arr-002-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-announces-fda-clearance-of-arr-002-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4110","AVBP","BK4588","LABU","BK4585","ARR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arrivent.com","stockEarnings":[{"period":"1week","weight":0.2269},{"period":"1month","weight":0.1093},{"period":"3month","weight":0.4123},{"period":"6month","weight":0.3402},{"period":"1year","weight":0.4564},{"period":"ytd","weight":0.6446}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.046},{"period":"3month","weight":0.126},{"period":"6month","weight":0.1041},{"period":"1year","weight":0.2704},{"period":"ytd","weight":0.1102}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.","exchange":"NASDAQ","name":"ArriVent BioPharma","nameEN":"ArriVent BioPharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ArriVent BioPharma(AVBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ArriVent BioPharma,AVBP,ArriVent BioPharma股票,ArriVent BioPharma股票老虎,ArriVent BioPharma股票老虎国际,ArriVent BioPharma行情,ArriVent BioPharma股票行情,ArriVent BioPharma股价,ArriVent BioPharma股市,ArriVent BioPharma股票价格,ArriVent BioPharma股票交易,ArriVent BioPharma股票购买,ArriVent BioPharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ArriVent BioPharma(AVBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ArriVent BioPharma(AVBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}